Anti-inflammatory properties of prostaglandin E2: deletion of microsomal prostaglandin E synthase-1 exacerbates non-immune inflammatory arthritis in mice.
Prostanoids and PGE2 in particular have been long viewed as one of the major mediators of inflammation in arthritis. However, experimental data indicate that PGE2 can serve both pro- and anti-inflammatory functions. We have previously shown (Kojima et al., J. Immunol. 180 (2008) 8361-8368) that microsomal prostaglandin E synthase-1 (mPGES-1) deletion, which regulates PGE2 production, resulted in the suppression of collagen-induced arthritis (CIA) in mice. This suppression was attributable, at least in part, to the impaired generation of type II collagen autoantibodies. In order to examine the function of mPGES-1 and PGE2 in a non-autoimmune form of arthritis, we used the collagen antibody-induced arthritis (CAIA) model in mice deficient in mPGES-1, thereby bypassing the engagement of the adaptive immune response in arthritis development. Here we report that mPGES-1 deletion significantly increased CAIA disease severity. The latter was associated with a significant (~3.6) upregulation of neutrophil, but not macrophage, recruitment to the inflamed joints. The lipidomic analysis of the arthritic mouse paws by quantitative liquid chromatography/tandem mass-spectrometry (LC/MS/MS) revealed a dramatic (~59-fold) reduction of PGE2 at the peak of arthritis. Altogether, this study highlights mPGES-1 and its product PGE2 as important negative regulators of neutrophil-mediated inflammation and suggests that specific mPGES-1 inhibitors may have differential effects on different types of inflammation. Furthermore, neutrophil-mediated diseases could be exacerbated by inhibition of mPGES-1.
Division of Rheumatology, Department of Internal Medicine, University of Kentucky, Lexington, KY 40536, USA.
Andrey
A
Frolov
Lihua
L
Yang
Hua
H
Dong
Bruce D
BD
Hammock
Leslie J
LJ
Crofford
D000818:Animals; D001169:Arthritis, Experimental / Q000235:genetics / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D001323:Autoantibodies / Q000096:biosynthesis / Q000276:immunology; D002853:Chromatography, Liquid; D024043:Collagen Type II / Q000235:genetics / Q000276:immunology; D015232:Dinoprostone / Q000276:immunology / Q000378:metabolism*; D005260:Female; D017353:Gene Deletion; D007249:Inflammation / Q000235:genetics / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D019746:Intramolecular Oxidoreductases / Q000172:deficiency / Q000235:genetics*; D007596:Joints / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D050356:Lipid Metabolism / Q000276:immunology; D008264:Macrophages / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D020556:Neutrophil Infiltration / Q000276:immunology; D009504:Neutrophils / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D000071876:Prostaglandin-E Synthases; D012720:Severity of Illness Index; D053719:Tandem Mass Spectrometry
D001323:Autoantibodies; D024043:Collagen Type II; D019746:Intramolecular Oxidoreductases; D000071876:Prostaglandin-E Synthases; C000605865:Ptges protein, mouse; D015232:Dinoprostone
(±)14(15)-epoxy-5Z,8Z,11Z-eicosatrienoic acid; (±)14,15-dihydroxy-5Z,8Z,11Z-eicosatrienoic acid; (±)9(10)-epoxy-12Z-octadecenoic acid; (±)9,10-dihydroxy-12Z-octadecenoic acid; 11-HETE; 11-hydroxyeicosatetraenoic acid; 14,15-DiHETrE; 14,15-EpETrE; 15-HETE; 15-hydroxyeicosatetraenoic acid; 5-HETE; 5-hydroxyeicosatetraenoic acid; 9,10-DiHOME; 9,10-EpOME; 9-HETE; 9-hydroxyeicosatetraenoic acid; ARA; Arthritis; IL-6; Inflammation; LC/MS/MS; MPO; PGD2; PGE2; PGF2a; Prostaglandin; RA; arachidonic acid; interleukin 6; liquid chromatography/tandem mass spectrometry; mPGES-1; myeloperoxidase; prostaglandin D2; prostaglandin E2; prostaglandin F2a; rheumatoid arthritis; rheumatoid 